Autoinflammatory & rare systemic diseases
Systematic Review and Metaanalysis of Pharmacological Interventions in Adult-Onset Still Disease and the Role of Biologic Disease-Modifying Antirheumatic Drugs
Authors' conclusion
Evidence supports TCZ, ANK, and CNK therapy for AOSD. However, the magnitude of effect and comparative effectiveness of treatments is uncertain.
Study context
- Population
- People with adult-onset Still disease (AOSD); studies January 2012 to February 202344 studies
- Comparison
- Pharmacological interventions for AOSD
- Outcome
- Rates of remission and response, discontinuation of concurrent treatments, complications of AOSD, treatment-related adverse events
Methodological detailsCochrane risk of bias tool, Joanna Briggs Institute tool for case series
- Cochrane risk of bias tool
- Joanna Briggs Institute tool for case series
Pooled result
As reported in the abstract
Complete remission (pooled rate)
Complete remission (pooled rate) TCZ 80% (95% CI 59–92%) · ANK 73% (95% CI 58–84%) · CNK 77% (95% CI 29–97%)
I2
Further pooled results
CS discontinuation (pooled rate) TCZ 57% (95% CI 29–81%) · ANK 47% (95% CI 18–78%) · CNK 34% (95% CI 6–81%)
I2
Corticosteroids (CS) discontinuation vs proportion previously treated with bDMARDs
- Trend toward lower CS discontinuation with higher proportion previously treated with bDMARDs
- P = 0.05
Original publication
Systematic Review and Metaanalysis of Pharmacological Interventions in Adult-Onset Still Disease and the Role of Biologic Disease-Modifying Antirheumatic Drugs. J Rheumatol. Published 1 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →